Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra A Springer

Showing results (71-80 of 121) with videos related to

Pageof 13
Sort By:
Contemporary Clinical Trials|November 22, 2011
Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community - a potential conduit to improved HIV treatment outcomesAli Shabahang Saber-Tehrani, Sandra A Springer, Jingjun Qiu, et al.
Contemporary Clinical Trials|September 22, 2014
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the communityAngela Di Paola, Thomas Lincoln, Daniel J Skiest, et al.
JAMA Internal Medicine|April 2, 2014
Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gateJaimie P Meyer, Javier Cepeda, Johnny Wu, et al.
AIDS (London, England)|August 23, 2020
Preventing HIV outbreaks among people who inject drugs in the United States: plus ça change, plus ça même choseSteffanie A Strathdee, Irene Kuo, Nabila El-Bassel, et al.
Drug and Alcohol Dependence|March 24, 2017
Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the communitySandra A Springer, Angela Di Paola, Marwan M Azar, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 23, 2007
Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trialFrederick L Altice, Duncan Smith-Rohrberg Maru, R Douglas Bruce, et al.
Contemporary Clinical Trials Communications|January 25, 2021
Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorderBreanne E Biondi, Subhasis Mohanty, Brent Vander Wyk, et al.
Current HIV/AIDS Reports|September 29, 2015
The Impact of Alcohol Use and Related Disorders on the HIV Continuum of Care: a Systematic Review : Alcohol and the HIV Continuum of CarePanagiotis Vagenas, Marwan M Azar, Michael M Copenhaver, et al.
Journal of Substance Abuse Treatment|August 3, 2019
Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomesIuliia Makarenko, Iryna Pykalo, Sandra A Springer, et al.
Journal of Substance Abuse Treatment|March 29, 2014
An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexonePanagiotis Vagenas, Angela Di Paola, Maua Herme, et al.
Pageof 13

Showing results (71-80 of 121) with videos related to

Sort By:
Pageof 13
Contemporary Clinical Trials|November 22, 2011
Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community - a potential conduit to improved HIV treatment outcomesAli Shabahang Saber-Tehrani, Sandra A Springer, Jingjun Qiu, et al.
Contemporary Clinical Trials|September 22, 2014
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the communityAngela Di Paola, Thomas Lincoln, Daniel J Skiest, et al.
JAMA Internal Medicine|April 2, 2014
Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gateJaimie P Meyer, Javier Cepeda, Johnny Wu, et al.
AIDS (London, England)|August 23, 2020
Preventing HIV outbreaks among people who inject drugs in the United States: plus ça change, plus ça même choseSteffanie A Strathdee, Irene Kuo, Nabila El-Bassel, et al.
Drug and Alcohol Dependence|March 24, 2017
Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the communitySandra A Springer, Angela Di Paola, Marwan M Azar, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 23, 2007
Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trialFrederick L Altice, Duncan Smith-Rohrberg Maru, R Douglas Bruce, et al.
Contemporary Clinical Trials Communications|January 25, 2021
Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorderBreanne E Biondi, Subhasis Mohanty, Brent Vander Wyk, et al.
Current HIV/AIDS Reports|September 29, 2015
The Impact of Alcohol Use and Related Disorders on the HIV Continuum of Care: a Systematic Review : Alcohol and the HIV Continuum of CarePanagiotis Vagenas, Marwan M Azar, Michael M Copenhaver, et al.
Journal of Substance Abuse Treatment|August 3, 2019
Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomesIuliia Makarenko, Iryna Pykalo, Sandra A Springer, et al.
Journal of Substance Abuse Treatment|March 29, 2014
An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexonePanagiotis Vagenas, Angela Di Paola, Maua Herme, et al.
Pageof 13